ZURA
Zura Bio Limited
$5.35
+0.81
(+17.84%)
Mkt Cap
295.20M
Volume
8,153,625
52W Range
1-7.44
Sector
Healthcare
Beta
0.03
EPS (TTM)
-1.09
P/E Ratio
-4.94
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$5.35
Fair Value
moderate signal
15.2% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Stable Earnings Power
29.3 / 100 pillar composite (overridden)
Steady, predictable earnings power — graded A–F vs. similar companies.
Company Description
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Net Income | (68.65M) | (52.40M) | (60.36M) | (25.74M) | 8.42M |
| EPS | -1.06 | -0.60 | -2.09 | 0.21 | 0.40 |
| Free Cash Flow | (64.93M) | (28.15M) | (23.05M) | (13.20M) | (1.10M) |
| FCF / Share | -0.69 | -0.37 | -0.70 | -0.77 | -0.06 |
| Operating CF | (64.81M) | (28.08M) | (15.05M) | (1.20M) | (1.10M) |
| Total Assets | 113.95M | 179.53M | 100.84M | 5.26M | 140.55M |
| Total Debt | 0 | 0 | 0 | 7.76M | 0 |
| Cash & Equiv | 109.41M | 176.50M | 99.81M | 1.57M | 729,223 |
| Book Value | 101.54M | 146.81M | 59.33M | (32.06M) | 130.20M |
| Return on Equity | -0.68 | -0.36 | -1.02 | N/A | 0.06 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (24.22M) | (17.18M) | (18.04M) | (15.99M) | (17.44M) | (9.05M) | (20.70M) | (10.33M) | (7.75M) | (8.47M) | (8.27M) | (34.02M) |
| EPS | -0.22 | -0.49 | -0.21 | -0.17 | -0.19 | -0.14 | -0.26 | -0.17 | -0.02 | -0.18 | -0.18 | -0.99 |
| Free Cash Flow | (18.94M) | (22.30M) | (15.48M) | (16.05M) | (11.11M) | (10.87M) | (5.67M) | (6.63M) | (9.99M) | (4.05M) | (4.82M) | (10.92M) |
| FCF / Share | -0.17 | -0.24 | -0.16 | -0.17 | -0.17 | -0.17 | -0.06 | -0.09 | -0.21 | -0.09 | -0.10 | -0.32 |
| Operating CF | (18.92M) | (22.28M) | (15.44M) | (16.03M) | (11.06M) | (10.82M) | (5.65M) | (6.62M) | (4.98M) | (4.05M) | (2.57M) | (5.17M) |
| Total Assets | 228.64M | 113.95M | 143.94M | 157.81M | 172.50M | 179.53M | 189.07M | 189.50M | 90.48M | 100.84M | 104.59M | 113.33M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 225.59M | 109.41M | 139.02M | 154.49M | 170.57M | 176.50M | 188.22M | 188.44M | 89.82M | 99.81M | 103.86M | 112.80M |
| Book Value | 216.90M | 101.54M | 108.24M | 125.91M | 138.20M | 146.81M | 153.05M | 156.52M | 61.01M | 59.33M | 63.21M | 68.91M |
| Return on Equity | -0.11 | -0.17 | -0.17 | -0.13 | -0.13 | -0.06 | -0.14 | -0.07 | -0.13 | -0.14 | -0.13 | -0.49 |
ZURA News
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of “Moderate Buy” by Analysts
Analysts Set Zura Bio Limited (NASDAQ:ZURA) Price Target at $11.60
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress
Zura Bio to Participate in Upcoming Investor Conferences
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares